Long, G. V., Saw, R. P. M., Lo, S., Nieweg, O. E., Shannon, K. F., Gonzalez, M., Guminski, A., Lee, J. H., Lee, H., Ferguson, P. M., Rawson, R. V., Wilmott, J. S., Thompson, J. F., Kefford, R. F., Ch'ng, S., Stretch, J. R., Emmett, L., Kapoor, R., Rizos, H., Spillane, A. J., Scolyer, R. A., & Menzies, A. M. (2019). neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet oncology, 20(7), 961–971. http://access.bl.uk/ark:/81055/vdc_100086499042.0x00000e